The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group found insufficient evidence to recommend prostate cancer antigen 3 (PCA3) testing to inform decisions for when ...

In the third study, Roobol et al. 7 examined the performance of PCA3 score as a first-line diagnostic test similar to the current use of PSA measurement. The study evaluated nearly 1,000 men from a ...

Data Bridge Market Research conducted a recent market intelligence study, thoroughly analysing the Prostate Cancer Antigen 3 (PCA3) Test Market. The newly published report employs an appealing layout ...

Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. Germ-line single nucleotide ...

Currently, early detection of prostate cancer depends on an abnormal digital rectal examination and an elevated prostate-specific-antigen (PSA) level requiring a prostate biopsy, often associated with ...

Prostate cancer is one of the largest killers among males worldwide. Until recently, prostate cancer diagnosis has relied on a combination of prostate-specific antigen (PSA) level, digital rectal ...

In the European Randomised Study of Screening for Prostate Cancer (ERSPC) trial, PCA3 was assessed as a first line-screening test. 40 While the positive predictive values of a PCA3 score of 10 or ...

QUEBEC CITY, May 25, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 ...

The clinical study leading to FDA approval of the PCA3 test in February of 2012 was a multicenter study from 14 clinical sites. The study included 466 men aged 50 years or older who had at least one ...

Global Prostate Cancer Antigen 3 (PCA3) Test Market Overview: For drawing up sustainable, money-making, and profitable business strategies, the winning Prostate Cancer Antigen 3 (PCA3) Test Market ...

Diagnostic combines PCA3 and three other RNAs, including a gene fusion, according to Cancer Research paper. An experimental biomarker test more accurately detects prostate cancer than any other ...

Last week brought more positive news for DiagnoCure Inc. (T.CUR) and the Progensa PCA3 prostate cancer test including the final recommendation by the U.S. Preventative Services Task Force (:USPSTF) ...